NCT04788043 2025-04-02Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin LymphomaStanford UniversityPhase 2 Active not recruiting8 enrolled
NCT05929716 2023-11-13An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell LymphomaM.D. Anderson Cancer CenterPhase 2 Withdrawn